IN PRIMARY NEURONAL CULTURES MUSCARINIC M1 AND M3 RECEPTOR MESSENGER-RNA LEVELS ARE REGULATED BY AGONISTS, PARTIAL AGONISTS AND ANTAGONISTS

被引:8
|
作者
BRUSA, R
GAMALERO, SR
GENAZZANI, E
EVA, C
机构
[1] Istituto di Farmacologia e Terapia Sperimentale, University of Torino, 10125 Torino, Via Pietro Giuria
关键词
MUSCARINIC RECEPTOR; MESSENGER RNA REGULATION; POLYMERASE CHAIN REACTION; PRIMARY NEURONAL CULTURE;
D O I
10.1016/0922-4106(95)90162-0
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The homologous regulation of the muscarinic m1 and m3 receptors mRNA was studied in rat corticostriatal neuronal cultures. In response to the full agonist carbachol the m1 and m3 receptor mRNA levels were modulated and showed different time-courses. The m1 receptor mRNA increased to 270% of prestimulation levels after 6 h, while the m3 receptor transcript transiently increased to 170% after 2 h. Conversely, the muscarinic receptor partial agonist oxotremorine caused a rapid and sustained increase in both mRNA species as soon as after 1 h of exposure. A comparable increase in both receptor mRNAs was induced by the partial agonist [4-(m-chlorophenylcarbamoyloxy)-2-butynyltrimethyl-ammonium chloride] (McN-A-343). The observation that 1 h exposure to the non selective antagonist N-methyl-scopolamine also enhanced the mi and m3 receptor transcripts suggests that in corticostriatal neurons muscarinic receptor partial agonists exert an antagonist-like effect on the m1 and m3 receptor mRNAs.
引用
收藏
页码:9 / 16
页数:8
相关论文
共 50 条
  • [1] Acylhydrazones as M1/M3 selective muscarinic agonists
    Wu, ESC
    Kover, A
    Loch, JT
    Rosenberg, LP
    Semus, SF
    Verhoest, PR
    Gordon, JC
    Machulskis, AC
    McCreedy, SA
    Zongrone, J
    Blosser, JC
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1996, 6 (21) : 2525 - 2530
  • [2] Acylhydrazones as M1/M3 selective muscarinic agonists.
    Wu, ESC
    Kover, A
    Loch, JT
    Rosenberg, P
    Semus, S
    Verhoest, PR
    Gordon, J
    Machulskis, A
    McCreedy, SA
    Blosser, JC
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1996, 211 : 34 - MEDI
  • [3] Rational Design of Partial Agonists for the Muscarinic M1 Acetylcholine Receptor
    Chen, Xinyu
    Kloeckner, Jessika
    Holze, Janine
    Zimmermann, Cornelia
    Seemann, Wiebke K.
    Schrage, Ramona
    Bock, Andreas
    Mohr, Klaus
    Traenkle, Christian
    Holzgrabe, Ulrike
    Decker, Michael
    JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (02) : 560 - 576
  • [4] PARTIAL M1 BUT NOT M3 MUSCARINIC AGONISTS REVERSE SCOPOLAMINE-INDUCED MEMORY IMPAIRMENT IN RATS
    BLOSSER, J
    WIDZOWSKI, DV
    BIALOBOK, P
    KUCERA, K
    SITAR, S
    MCCREEDY, S
    MACHULSKIS, A
    MULLEN, G
    WU, E
    MURRAY, R
    GORDON, J
    NEUROBIOLOGY OF AGING, 1994, 15 : S103 - S103
  • [5] Muscarinic M1 receptor agonists and M2 receptor antagonists as therapeutic targets in Alzheimer's disease
    Sheardown, MJ
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2002, 12 (06) : 863 - 870
  • [6] Mechanisms of activation of the M1 muscarinic receptor by atypical and classical agonists
    Randakova, A.
    Santruckova, E.
    Zimcik, P.
    Jakubik, J.
    El-Fakahany, E. E.
    Dolezal, V.
    JOURNAL OF NEUROCHEMISTRY, 2013, 125 : 150 - 150
  • [7] Muscarinic M1 receptor agonists: can they improve cognitive performance?
    Scarr, Elizabeth
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2013, 16 (04): : 717 - 720
  • [8] Industrially Viable Preparation of (R)-3-Quinuclidinol, a Key Building Block of Muscarine M1, M3 Agonists and M3 Antagonists
    Chavakula, Ramadas
    Mutyala, Narayana Rao
    Chennupati, Srinivasa Rao
    ORGANIC PREPARATIONS AND PROCEDURES INTERNATIONAL, 2013, 45 (06) : 507 - 509
  • [9] Pfizer's dual-acting β2 agonists/muscarinic M3 antagonists
    Norman, Peter
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2008, 18 (09) : 1091 - 1096
  • [10] Selectivity of Agonists for the Active State of M1 to M4 Muscarinic Receptor Subtypes
    Figueroa, Katherine W.
    Griffin, Michael T.
    Ehlert, Frederick J.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2009, 328 (01): : 331 - 342